Exploring Molecular Reorientations in Amorphous and Recrystallized Felodipine at the Microscopic Level

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 May 6

PMID 35521258

Authors

A Pajzderska

J Jenczyk

J P Embs

J Wasicki

Affiliations

Soon will be listed here.

Abstract

Molecular reorientations were studied in amorphous, partially and fully recrystallized felodipine (calcium channel blocker, a drug from the family of 1',4-dihydropyridine) using a set of experimental methods: high-resolution solid-state nuclear magnetic resonance (NMR), relaxometry NMR and quasielastic neutron scattering (QENS). The results were compared with molecular dynamics in crystalline felodipine previously investigated [A. Pajzderska, K. Drużbicki, M. A. Gonzalez, J. Jenczyk, J. Mielcarek, J. Wąsicki, Diversity of Methyl Group Dynamics in Felodipine: a DFT Supported NMR and Neutron Scattering Study, , 2018, , 7371-7385]. The kinetics of the recrystallization was also studied. The most stable sample was the sample stored in a closed ampoule (at room temperature, in 0% RH) and its complete recrystallization lasted 105 days. In the fully recrystallized sample, the same molecular reorientation identified in the crystalline form was detected, so reorientations of all methyl groups and the ethyl ester fragment. In the partially recrystallized sample, static disorder caused by the two positions of both side chains was revealed. In the amorphous sample the reorientation of all methyl groups was analyzed and the distribution of correlation times and energy barriers connected with the loss of long-range ordering and disorder of side chains were analyzed. Additionally, inhibition of reorientation in the ethyl ester fragment was observed.

Citing Articles

Monitoring of Isothermal Crystallization and Time-Temperature Transformation of Amorphous Felodipine: The Time-Domain Nuclear Magnetic Resonance Method.

Pajzderska A, Gonzalez M, Jarek M, Wasicki J AAPS PharmSciTech. 2024; 25(7):219.

PMID: 39299994 DOI: 10.1208/s12249-024-02919-2.

References

Azuah R, Kneller L, Qiu Y, Tregenna-Piggott P, Brown C, Copley J . DAVE: A Comprehensive Software Suite for the Reduction, Visualization, and Analysis of Low Energy Neutron Spectroscopic Data. J Res Natl Inst Stand Technol. 2016; 114(6):341-58. PMC: 4646530. DOI: 10.6028/jres.114.025. View

Pajzderska A, Mielcarek J, Wasicki J . Complex and mixture of β-cyclodextrin with diazepam characterised by ¹H NMR and atom-atom potential methods. Carbohydr Res. 2014; 398:56-62. DOI: 10.1016/j.carres.2014.07.025. View

Qi S, Belton P, Nollenberger K, Clayden N, Reading M, Craig D . Characterisation and prediction of phase separation in hot-melt extruded solid dispersions: a thermal, microscopic and NMR relaxometry study. Pharm Res. 2010; 27(9):1869-83. DOI: 10.1007/s11095-010-0185-8. View

Konno H, Taylor L . Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci. 2006; 95(12):2692-705. DOI: 10.1002/jps.20697. View

Alie J, Menegotto J, Cardon P, Duplaa H, Caron A, Lacabanne C . Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance. J Pharm Sci. 2003; 93(1):218-33. DOI: 10.1002/jps.10520. View

Abernethy D, Schwartz J . Calcium-antagonist drugs. N Engl J Med. 1999; 341(19):1447-57. DOI: 10.1056/NEJM199911043411907. View

Marsac P, Rumondor A, Nivens D, Kestur U, Stanciu L, Taylor L . Effect of temperature and moisture on the miscibility of amorphous dispersions of felodipine and poly(vinyl pyrrolidone). J Pharm Sci. 2009; 99(1):169-85. DOI: 10.1002/jps.21809. View

Miura H, Kanebako M, Shirai H, Nakao H, Inagi T, Terada K . Stability of amorphous drug, 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one, in silica mesopores and measurement of its molecular mobility by solid-state (13)C NMR spectroscopy. Int J Pharm. 2011; 410(1-2):61-7. DOI: 10.1016/j.ijpharm.2011.03.030. View

Rumondor A, Stanford L, Taylor L . Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. Pharm Res. 2009; 26(12):2599-606. DOI: 10.1007/s11095-009-9974-3. View

10.

Masuda K, Tabata S, Sakata Y, Hayase T, Yonemochi E, Terada K . Comparison of molecular mobility in the glassy state between amorphous indomethacin and salicin based on spin-lattice relaxation times. Pharm Res. 2005; 22(5):797-805. DOI: 10.1007/s11095-005-2597-4. View

11.

Pajzderska A, Jarek M, Mielcarek J, Wasicki J . Analysis of the Distribution of Energy Barriers in Amorphous Diazepam on the Basis of Computationally Supported NMR Relaxation Data. J Phys Chem B. 2016; 120(41):10723-10728. DOI: 10.1021/acs.jpcb.6b08482. View

12.

Aso Y, Yoshioka S, Kojima S . Relationship between the crystallization rates of amorphous nifedipine, phenobarbital, and flopropione, and their molecular mobility as measured by their enthalpy relaxation and (1)H NMR relaxation times. J Pharm Sci. 2000; 89(3):408-16. DOI: 10.1002/(SICI)1520-6017(200003)89:3<408::AID-JPS11>3.0.CO;2-#. View

13.

Konno H, Taylor L . Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture. Pharm Res. 2007; 25(4):969-78. DOI: 10.1007/s11095-007-9331-3. View

14.

Yoshioka S, Aso Y . Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals. J Pharm Sci. 2007; 96(5):960-81. DOI: 10.1002/jps.20926. View

15.

Baghel S, Cathcart H, OReilly N . Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs. J Pharm Sci. 2016; 105(9):2527-2544. DOI: 10.1016/j.xphs.2015.10.008. View

16.

Knapik J, Wojnarowska Z, Grzybowska K, Hawelek L, Sawicki W, Wlodarski K . Physical stability of the amorphous anticholesterol agent (ezetimibe): the role of molecular mobility. Mol Pharm. 2014; 11(11):4280-90. DOI: 10.1021/mp500498e. View

17.

Marsac P, Konno H, Taylor L . A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res. 2006; 23(10):2306-16. DOI: 10.1007/s11095-006-9047-9. View

18.

Paudel A, Geppi M, Van den Mooter G . Structural and dynamic properties of amorphous solid dispersions: the role of solid-state nuclear magnetic resonance spectroscopy and relaxometry. J Pharm Sci. 2014; 103(9):2635-2662. DOI: 10.1002/jps.23966. View

19.

Fossheim R . Crystal structure of the dihydropyridine Ca2+ antagonist felodipine. Dihydropyridine binding prerequisites assessed from crystallographic data. J Med Chem. 1986; 29(2):305-7. DOI: 10.1021/jm00152a023. View

20.

Lobenberg R, Amidon G . Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm. 2000; 50(1):3-12. DOI: 10.1016/s0939-6411(00)00091-6. View